Stevanato Group reported second quarter fiscal 2026 revenue of €302.0 million, an 8% increase year-over-year, driven by a 9% rise in its Biopharmaceutical and Diagnostic Solutions segment. The company completed the divestiture of Balda C. Brewer, Inc., recording €12.2 million in related expenses that reduced diluted earnings per share to €0.08; adjusted diluted EPS was €0.14. Gross profit margin expanded 60 basis points to 28.7%, while adjusted EBITDA margin improved 280 basis points to 26.0%. Management updated full-year guidance, projecting revenue between €1.260 billion and €1.280 billion, adjusted EBITDA of €335.0 million to €345.2 million, and adjusted diluted EPS of €0.60 to €0.62. Stevanato Group is a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries.
